Effects of COVID-19 pandemic on conduct of clinical trials.
Akacha, M., Branson, J., Bretz, F., Dharan, B., Gallo, P., Gathmann, I., Hemmings, R., Jones, J., Xi, D., & Zuber, E. (2020). Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials. Statistics in Biopharmaceutical Research, 12(4), 419-426.
Akacha, M., Bretz, F., Ohlssen, D., Rosenkranz, G., & Schmidli, H. (2017). Estimands and their role in clinical trials. Statistics in Biopharmaceutical Research, 9(3), 268-271.
Brown, E. E., Kumar, S., Rajji, T. K., Pollock, B. G., & Mulsant, B. H. (2020). Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. The American Journal of Geriatric Psychiatry, 28(7), 712–721.
Cawthon, P. M., Orwoll, E. S., Ensrud, K. E., Cauley, J. A., Kritchevsky, S. B., Cummings, S. R., & Newman, A. (2020). Assessing the Impact of the COVID-19 Pandemic and Accompanying Mitigation Efforts on Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences, 75(9), e123–e125.
Davis, S., & Pai, S. (2020). Challenges and opportunities for sponsors in conducting clinical trials during a pandemic. Perspectives in Clinical Research, 11(3), 115-120.
Depner, C. M., Cheng, P. C., Devine, J. K., Khosla, S., De Zambotti, M., Robillard, R., Vakulin, A., & Drummond, S. P. (2020). Wearable technologies for developing sleep and circadian biomarkers: A summary of workshop discussions. Sleep, 43(2), zsz254.
Fleming, P. F., Gale, C., Molloy, E. J., Faust, S. N., Costeloe, K., Juszczak, E., & Roehr, C. C. (2021). Paediatric research in the times of COVID-19. Pediatric Research, 90(2), 267–271.
Fleming, T. R. (2011). Addressing missing data in clinical trials. Annals of Internal Medicine, 154(2), 113–117.
Fleming, T. R., Labriola, D., & Wittes, J. (2020). Conducting clinical research during the COVID-19 pandemic: Protecting scientific integrity. Jama, 324(1), 33–34.
Food, U. S., & Administration, D. (2020). FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic: Guidance for Industry, Investigators, and Institutional Review Boards [Updated on April 16, 2020]. United States. Food and Drug Administration.
Ich, C. (2019). ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
Kim, J. H., Marks, F., & Clemens, J. D. (2021). Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine, 27(2), 205–211.
Lenze, E. J., Mattar, C., Zorumski, C. F., Stevens, A., Schweiger, J., Nicol, G. E., Miller, J. P., Yang, L., Yingling, M., & Avidan, M. S. (2020). Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. Jama, 324(22), 2292–2300.
Marshall, A. S., Sadarangani, M., Scrivens, A., Williams, R., Yong, J., Bowler, U., Linsell, L., Chiocchia, V., Bell, J. L., & Stokes, C. (2020). Study protocol: NeoCLEAR: Neonatal Champagne Lumbar punctures Every time–An RCT: a multicentre, randomised controlled 2$times$ 2 factorial trial to investigate techniques to increase lumbar puncture success. BMC Pediatrics, 20(1), 1–10.
McDermott, M. M., & Newman, A. B. (2020). Preserving clinical trial integrity during the coronavirus pandemic. Jama, 323(21), 2135–2136.
McDermott, M. M., & Newman, A. B. (2021). Remote research and clinical trial integrity during and after the coronavirus pandemic. Jama, 325(19), 1935–1936.
McDermott, M. M., Spring, B., Tian, L., Treat-Jacobson, D., Ferrucci, L., Lloyd-Jones, D., Zhao, L., Polonsky, T., Kibbe, M. R., & Bazzano, L. (2021). Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: The LITE randomized clinical trial. JAMA, 325(13), 1266–1276.
Meyer, R. D., Ratitch, B., Wolbers, M., Marchenko, O., Quan, H., Li, D., Fletcher, C., Li, X., Wright, D., & Shentu, Y. (2020). Statistical issues and recommendations for clinical trials conducted during the COVID-19 pandemic. Statistics in Biopharmaceutical Research, 12(4), 399–411.
Molenberghs, G., & Kenward, M. (2007). Missing data in clinical studies. John Wiley & Sons.
Organization, W. H. (2020). Novel Coronavirus ( 2019-nCoV): Situation report, 11.
Rubio-San-Simón, A., André, N., Cefalo, M. G., Aerts, I., Castañeda, A., Benezech, S., Makin, G., van Eijkelenburg, N., Nysom, K., & Marshall, L. (2020). Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 141, 82–91.
Wolkewitz, M., & Puljak, L. (2020). Methodological challenges of analysing COVID-19 data during the pandemic. BMC medical research methodology, 20(1), 81.
Copyright (c) 2022 Medha Joshi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.